

REVIEW OF DECISIONS

BOARD MEETING

23-24 June 2021, Virtual Meeting



Reach every child

www.gavi.org

Decision 1: CEO Appointment – Exceptional 12-month Extension

The Gavi Alliance Board:

Approved that Dr Seth Berkley be reappointed as Chief Executive Officer (CEO), an Officer with individual signatory authority on behalf of the Gavi Alliance, for a further exceptional one-year term effective 3 August 2022.

Decision 2: Consent Agenda: Board and Committee Member Appointments (1/2)

The Gavi Alliance Board:

- a) **Appointed Awa Marie Coll Seck** as an Unaffiliated Board member in the seat currently held by Stephen Zinser effective 1 July 2021 and until 30 June 2024
- b) **Appointed Naguib Kheraj** as an Unaffiliated Board member in the seat currently held by William Roedy effective 1 August 2021 and until 31 July 2024
- c) **Appointed Bounfeng Phoummalaysith** of Lao PDR as Alternate Board Member representing the implementing country constituency in the seat formerly held by Bounkong Syhavong of Lao PDR, effective immediately and until 31 December 2023
- d) **Appointed** the following to the Governance Committee effective 1 August 2021:
 - **An Vermeersch** (Alternate Board Member) until 31 December 2021

Decision 2: Consent Agenda: Board and Committee Member Appointments (2/2)

- e) **Appointed** the following to the Audit and Finance Committee effective 1 August 2021:
- **Naguib Kheraj** (Board Member) until 31 December 2021
- f) **Appointed** the following to the Investment Committee effective 1 August 2021:
- **Naguib Kheraj** (Board Member) until 31 December 2021
- g) **Appointed** the following to the Programme and Policy Committee:
- **Ephrem Lemango** (Committee Delegate) effective immediately and until 31 Dec 2021
 - **Awa Marie Coll Seck** (Board Member) effective 1 July 2021 and until 31 Dec 2021

Decision 3: Consent Agenda: Committee Chair Appointments

The Gavi Alliance Board:

- a) **Appointed Afsaneh Beschloss** as Chair of the Investment Committee Chair effective 1 July 2021 and until 31 December 2021; and
- b) **Appointed James Hargreaves** as Chair of the Evaluation Advisory Committee effective 1 July 2021 and until 31 December 2021.

Decision 4: Consent Agenda: UNICEF Procurement Fees

The Gavi Alliance Board:

- a) **Approved**, within the overall Partners Engagement Framework,
 - i. the proposed UNICEF procurement fee of US\$ 28.7 million for 2022;
 - ii. A budget of US\$ 24.4 million for UNICEF Supply Division fees for the procurement of vaccines, related devices and yellow fever surveillance and diagnostics equipment in 2022; and
 - iii. A budget of US\$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2022.

- b) **Noted** that the procurement fee excludes any procurement activity related to COVAX.

Decision 5: Consent Agenda: Yellow Fever

The Gavi Alliance Board:

Approved an extension through the end of 2022 of the currently forecasted amount which remains within the initially approved envelope of US\$ 8.2 million authorised for the 2019-2021 period for costs related to the procurement and distribution of laboratory reagents, supplies, and equipment for yellow fever diagnostic capacity strengthening through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes as set forth in Annex A to Doc 01f.

Decision 6: Consent Agenda: Gavi 5.0 Measurement Framework

The Gavi Alliance Board **approved** the proposed targets for selected Gavi 5.0 mission and strategy performance indicators in Annex B to Doc 01f, noting that:

- a) The targets will be measured against a 2019 baseline;
- b) The targets are aligned with Immunization Agenda (IA) 2030;
- c) The targets are established under the assumption that COVID-19-related disruptions to immunisation programmes will be limited in 2021 and beyond; however if they are greater or extend longer than assumed the Secretariat may request the Board to adjust the targets; and
- d) Targets for remaining mission and strategy performance indicators in Annex C to Doc 01f will be brought for approval later this year.

Decision 7: Consent Agenda: Gavi 5.0: Market Shaping Strategy

The Gavi Alliance Board:

Approved the Market Shaping Strategy 5.0 as set out in Annex D to Doc 01f.

Decision 8: Consent Agenda: Vaccine Innovation Prioritisation Strategy

The Gavi Alliance Board:

Approved an initial investment of up to US\$ 5 million for the Vaccine Innovation Prioritisation Strategy (VIPS) for costs related to short-term (2021-2023) activities to provide guidance for and incentivise development of the three VIPS innovation priorities, namely clarifying the potential demand and willingness-to-pay, defining investment cases and understanding the need for and design of push and pull funding mechanisms, and generating evidence of programmatic impact.

Decision 9: Strategy, Programmes and Partnerships: Progress, Risks and Challenges

The Gavi Alliance Board:

Approved the updated Risk Appetite Statement attached as Annex A to Doc 03.

Decision 10: Financial Update, including forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee has reviewed the financial implications of the recommendations made by the Programme and Policy Committee at its meeting on 19-20 May 2021 as set out in Figure 2 of Doc 04a and concluded that these recommendations could be approved by the Board in accordance with the Programme Funding Policy;
- b) **Noted** that except for reflecting the financial implications for Gavi 5.0 of the recommendations made by the Programme and Policy Committee, no changes have been made to the Finance Forecast approved by the Audit and Finance Committee on 4 May 2021; and
- c) **Approved** the Financial Forecast for the Gavi 5.0 (2021-2025) Strategic Period as set out in Section B of Doc 04a.

Decision 11: COVAX AMC financial forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations from the Programme and Policy Committee as set out in Figure 3 of Doc 04b (COVAX AMC Financial Forecast) and concluded that these recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy; and
- b) **Approved** the 2021-2022 COVAX AMC Financial Forecast as presented in Section B of Doc 04b.

Decision 12: COVAX Update

The Gavi Alliance Board:

Approved the continued administration of the COVAX Facility by Gavi in 2022.

Decision 13: COVAX Update (1/3)

The Gavi Alliance Board:

- a) **Approved** Option 2 for the future participation model for Self-Financing Participants (SFPs) and the proposal to unify terms and conditions as set out in Annex E to Doc 06;

- b) **Approved** Gavi taking an active role in the provision of fast, responsive and flexible funding through the creation of a COVID-19 Delivery Support (CDS) envelope and cross-cutting delivery elements, with associated funding of at least US\$ 775 million, with the objective of ensuring successful rapid roll-out and scale-up of COVID-19 vaccines in the next six to twelve months;

Decision 13: COVAX Update (2/3)

- c) **Noted** that this funding will be complementary to other donor, multilateral development bank support and domestic resources and guided by principles of flexibility and rapid-responsiveness, equity in access across and within AMC economies, a needs-based approach and focus on mitigating delivery risks and idle doses;
- d) **Delegated** to the Secretariat with support from partners WHO and UNICEF, the authority to allot US\$ 250 million-US\$ 350 million of COVID-19 Delivery Support ~ (CDS) funds with flexible application of the Programme Funding policy including waiving the requirement for independent review, with the objective to disburse these funds from July onwards in 2021 utilising existing programmatic and fiduciary risk mitigation mechanisms such as those used in emergency and humanitarian contexts on a no regrets basis; and

Decision 13: COVAX Update (3/3)

- e) **Requested** the Secretariat to work with technical partners and donors providing funding for CDS and cross-cutting delivery elements to determine, by end July 2021, the appropriate operational approach and mechanism(s) for allocating and disbursing the remaining delivery support funds, and any additional funds contributed specifically for delivery, in support of the CDS objective with the speed, flexibility and responsiveness required to support AMC92 countries. Further requested that the Secretariat update the AFC and PPC on the operational approach, implementation progress and understanding of delivery funding gaps and resources required at their next meetings with a written update to the Board before the end of Q3 2021.

Decision 14: Fiduciary Risk Assurance and Financial Management Capacity Building

The Gavi Alliance Board:

- a) **Approved** the approach set forth in Annex B to Doc 07 to strengthen fiduciary risk assurance and financial management of Gavi grants in Gavi 5.0; and
- b) **Approved** the associated investment of US\$ 139 million for 2022-2025, in addition to the US\$ 25 million of bridge funding previously approved by the Board for 2021, for an overall amount of US\$ 164 million for the approach in Gavi 5.0 to be used for the duration of the strategic period (2021-2025).

Decision 15: Civil Society and Community Engagement Approach

The Gavi Alliance Board:

Approved the Civil Society and Community Engagement Approach as set out in Annex A to Doc 08, recognising the need to closely monitor, learn and refine and bring back to the PPC and Board for guidance as needed.

Dates for 2022 Gavi Alliance Board Meetings

6-7 April 2022 (Retreat)

22-23 June 2022

7-8 December 2022

Thank you



www.gavi.org